Chlamydia trachomatis is now recognized as the most prevalent cause of sexually transmitted disease in the United States with approximately four million cases being diagnosed annually.¹ Chronic infection with this organism in the female reproductive tract may lead to pelvic in?ammatory disease, salpingitis, ectopic pregnancy and infertility. Infants acquiring Chlamydia at birth are at signi?cant risk of developing conjunctivitis and pneumonia.²

It has been estimated that the annualized health care costs of Chlamydia infection and its sequelae are in excess of two billion dollars per year.¹ The clinical diagnosis of Chlamydia infections in females is not precise and may be confused with other etiologies. Misdiagnosis and improper treatment may lead to chronic infection and serious sequelae. The InSTIcheck™ Chlamydia test detects extracted genus speci? c chlamydia lipopolysaccharide (LPS) from cervical swabs, thus providing a signi?cant aid in the diagnosis of Chlamydia infection.

Chlamydia trachomatis is one of the most significant sexually transmitted human pathogens causing non-gonococcal urethritis, post-gonococcal urethritis, proctitis, cervicitis, infertility and endometritis. If early diagnosis and treatment fail, these infections can result in acute epidymitis in the male, or pelvic inflammatory disease and ectopic pregnancy in the female.

Unlike classical culture methods for identification which require 48-72 hours to produce results, the InSTIcheck™ Chlamydia test requires only 15 minutes...